Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Jack_Bailey
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
oncology
|
| gptkbp:founded |
2008
|
| gptkbp:founder |
gptkb:Kwok-Kin_Wong
gptkb:Norman_E._Sharpless |
| gptkbp:headquarters_location |
gptkb:Research_Triangle_Park,_North_Carolina
|
| https://www.w3.org/2000/01/rdf-schema#label |
G1 Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notable_drug |
gptkb:trilaciclib
|
| gptkbp:numberOfEmployees |
approximately 100 (as of 2023)
|
| gptkbp:product |
gptkb:lerociclib
gptkb:trilaciclib |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
CDK4/6 inhibitors
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:GTHX
|
| gptkbp:trilaciclib_FDA_approval |
2021
|
| gptkbp:trilaciclib_indication |
myelosuppression in small cell lung cancer
|
| gptkbp:website |
https://www.g1therapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Fred_Eshelman
|
| gptkbp:bfsLayer |
6
|